Ranbaxy Laboratories, Inc.

Sun Pharmaceutical Industries Limited

Mohan Prasad

Yatendra Kumar

Naresh Kumar

Sudershan Kumar Arora

Mahavir Singh Khanna

Rajesh Kumar Thaper

Swargam Sathyanarayana

Kaptan Singh

Jagdev Singh Jaryal

Gyanendra Pandey

Killol Patel

Anu Mittal

Ram Thaimattam

Shyam Sunder Verma

Shravan Kumar Singh

Dattatray Bapuso Patil

Hari Babu Matta

Anmol Kumar Ray

Anandam Vempali

Pankaj Sharma

Vinod Kumar Arora

Asok Nath

Hashim Nizar Poovanathil Nagoor Meeran

Ashok Prasad

Neela Praveen Kumar

Hiten Sharadchandra Mehta

Balaguru Murugesan

Neera Tewari

Tarun Kumar Singh

Neera Tiwari

Santosh Richhariya

Ramkinkar Santra

Satyananda Misra

Saridi Madhava Dileep Kumar

Md Abul Kalam Azad

Bakthavathsalan Vijayaraghavan

Subhash Dhar

Bhavin Prabhudas Thanki

Nitin Maheshwari

Sudhir Singh Sanwal

Seema Ahuja

Ira Saxena

Praveen Kumar Neela

Bhupendra Vashishta

Shallendra Kumar Singh

Prasenjit Prafulla Das

Javeena

Pranab Chatterjee

Rajesh Kumar

Sarbjot Singh Sokhi

Prabhat Giri

Dhiren C Barman

Deepak Mohanlal Jain

Maneck Khurana

Kapil Sharma

Abhay Tatiya

Sanjay Mahadeo Gade

Sayeed Mukhtar

Dinesh Shashidharan Nair

Roshan Ramesh Medhane

Rakesh Singh

Munish Kapoor

Gopal Singh Bisht

Azok Nath

Patil Dattatray Bapuso

Keshav Deo

Nagaraju Gottumukkala

Sachin Deorao Zade

Ajay Shankar Singh

Vinod George

Anil Saini

Mahivir Singh Khanna

Avinash Sheshrao Mane

Dattatray B Patil

The present disclosure provides a process for the preparation of ixazomib citrate.

Process for the preparation of ixazomib citrate

The present invention provides processes for the preparation of baricitinib of Formula I and an intermediate of Formula V. The present invention also provides the use of the intermediate of Formula V for the preparation of baricitinib. 

Process for the preparation of baricitinib and an intermediate thereof

The present invention provides processes for the preparation of ibrutinib, intermediate compounds of Formula VI and Formula VIII, and salts thereof. The processes of the present invention are commercially viable, cost-effective, environmentally friendly, and make use of inexpensive, non-hazardous, safe chemicals that are easy to handle.

Process for the preparation of ibrutinib

The present invention relates to a stable amorphous ticagrelor and a process for its preparation.

Stable amorphous ticagrelor and a process for its preparation

The present invention provides a crystalline Form I of afatinib dimaleate, its process for preparation and pharmaceutical composition thereof, and its use in the treatment of metastatic non-small cell lung cancer.

Crystalline form of afatinib dimaleate

The present invention provides a crystalline form of baricitinib characterized by an XRPD pattern substantially as depicted in FIG., a process for its preparation, a pharmaceutical composition comprising it, and its use for the treatment of JAK-associated diseases.

Crystalline form of baricitinib

The present invention provides a process for the preparation of baricitinib and an intermediate thereof. The present invention provides a convenient, economical, and industrially advantageous two-step process for the preparation of [4-(IH-pyrazol-4-yl)-7Hpyrrolo[2,3-d] pyrimidin-7-yl]methyl pivalate of Formula (II). The process of the present invention involves the use of an alkali or alkaline earth metal hydroxide, carbonate, or bicarbonate as a base for reacting 4-chloro-7H-pyrrolo[2,3-d]pyrimidine of Formula (III) with chloromethyl pivalate of Formula (IV), and the use of an unprotected pyrazole borolane of Formula (VIII) for the conversion of (4-chloro-7H-pyrrolo[2,3-d] pyrimidin-7-yl)methyl 2,2-dimethylpropanoate of Formula V into [4-(1H-pyrazol-4-yl)-7Hpyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate of Formula (II). The process of the present invention provides [4-(1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]methyl pivalate of Formula (I) in high yield.

The present invention provides a process for the preparation of pazopanib of Formula Ia or salts, and intermediates thereof.

Process for the preparation of pazopanib or salts thereof

The present invention provides a process for the preparation of 4-dimethylaminocrotonic acid of Formula (II) or its salts, which is used as an intermediate for the preparation of afatinib or its salts. 

Process for the preparation of 4-dimethylaminocrotonic acid

The present invention relates to a dapagliflozin-citric acid co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus. A dapagliflozin citric acid co-crystal. The dapagliflozin citric acid co-crystal of claim, characterized by X-ray powder diffraction peaks having d-spacing values at about 3.89, 3.90, 4.01, 4.35, 5.77, and 5.80.

Co-crystal of dapagliflozin with citric acid

The present invention relates to pure crystalline Form II of an L-malic acid salt of sunitinib and a process for its preparation. The invention further provides crystalline Form II of an L-malic acid salt of sunitinib having a purity of at least 97.0%. The invention also provides crystalline Form II of an L-malic acid salt of sunitinib substantially free of an anti-oxidant. The invention also provides crystalline Form II of L-malic acid salt of sunitinib which remains chemically pure on storage at 25&#xb0; C.&#xb1;2&#xb0; C. and 40&#xb0; C.&#xb1;2&#xb0; C. at a relative humidity of 60%&#xb1;5% and 75%&#xb1;5%, respectively, for at least 1 month.

Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation

The present invention relates to processes for the preparation of dasatinib and its intermediates.

Process for the preparation of dasatinib and its intermediates

The present invention relates to an ascorbic acid salt of sunitinib and a process for its preparation. The present invention further provides a crystalline Form I of an L-ascorbic acid salt of sunitinib.

Ascorbic acid salt of sunitinib

The present invention relates to a process for the preparation of crystalline Form I of methanesulfonate salt of dabigatran etexilate. (Formula (I)). The present invention does not require the isolation of the dabigatran etexilate intermediate. 

Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate

The present invention relates to the salts of dexlansoprazole in amorphous form. The present invention further relates to processes for the preparation of salts of dexlansoprazole.

Salts of dexlansoprazole and their preparation

Growing community of inventors

Gurgaon, India

Mohan Prasad